New research suggests that patients who come off new GLP-1 drugs like Wegovy and Mounjaro can put back on shed pounds much more quickly than those who end conventional diet and exercise plans.
Published data in a leading medical journal points out that while obese people often shed substantial amounts of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"People using these treatments need to be cognizant of the potential of rapid weight regain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to original weight in about 18 months.
Comparing Approaches
The analysis, which reviewed dozens of trials involving over 9,000 of participants, contrasted the effects of these new drugs with conventional dieting.
The team note that individuals who lose weight through dieting usually have a slower weight regain—approximately 100 grams monthly—after stopping.
Understanding the Fast Rebound
Nutrition scientists suggest the way of the injections is key to understanding the amplified weight return.
The injections mimic a body's own chemical called GLP-1, which moderates hunger.
"Long-term administration of GLP-1 levels several times higher than normal might result in the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement results in appetite is uncontrolled, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines advise the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals contend that, considering the likelihood of weight regain, the therapy should be considered long-term.
This view is supported by drug manufacturers, who note that the results "highlight the long-term nature of excess weight," akin to managing conditions like high blood pressure.
User Accounts
People who have stopped the medication describe a intense resurgence of hunger.
"It felt as if a switch that goes on and you're instantly ravenous," recalled one woman.
The struggle is exacerbated if patients have not established lasting dietary or behavioural changes during treatment.
Widespread Use
Figures suggest that a significant number of adults in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
Ultimately, researchers stress that while the jabs are powerful tools for weight loss, they are not a standalone solution and lasting health benefits relies on integrated behavioural support.
